According to this market research, the sales revenue of Rituximab in the Chinese market in 2016-2019 has an increasing trend. The sales revenue of Rituximab in China increases from CNY943 million in 2016 to CNY1.42 billion in 2019. The sales value of Rituximab in China was approximately CNY1.3 billion in 2020. It decreased 8.4% Year on Year. The reason for the sales decline is that the COVID-19 epidemic has impacted the hospitals’ overall operation. The CAGR of the sales value of Rituximab in China is 8.4% from 2016 to 2020.
The analyst analyzes that as the epidemic situation has been improved and the hospitals resume their operation, sales of Rituximab will have a recovery growth from 2021 to 2025. In addition, sales will also increase due to the market expansion. Compared to indications approved in some developed countries, Rituximab has fewer indications being approved in China. The only two approved indications are non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Thus, the possibility of the increased number of indications may bring new target patients for Rituximab. Besides, with the emergence of biosimilar drugs, Roche was no longer the monopoly in the Chinese Rituximab market. As a result, the price of Rituximab will be more affordable in the future, which will lead to an increase in sales volume.
Topics Covered:
- The impact of COVID-19 on China's Rituximab market
- Sales value and volume of China's Rituximab 2016-2020
- Competitive landscape of China's Rituximab market
- Prices of Rituximab in China
- Prices of Rituximab in China by regions and manufacturers
- Analysis of factors affecting the development of China's Rituximab market
- Prospect of China's Rituximab market from 2021 to 2025
Table of Contents
Samples
LOADING...
Companies Mentioned
- Genentech Inc
- Roche Pharma
- Shanghai Henlius Biotech, Inc.
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...
Table Information
Report Attribute | Details |
---|---|
Published | April 2021 |
Forecast Period | 2016 - 2025 |
Estimated Market Value ( CNY | CNY 942 Million |
Forecasted Market Value ( CNY | CNY 2086 Million |
Compound Annual Growth Rate | 9.2% |
Regions Covered | China |
No. of Companies Mentioned | 3 |